Enlivex Therapeutics (Nasdaq:ENLV) - Aandelenkoers, Nieuws & Analyse

ENLV Overzicht aandelen

Enlivex Therapeutics Ltd. is, samen met haar dochterondernemingen, actief als een bedrijf in Israël dat zich bezighoudt met macrofaagherprogrammering van immuuntherapieën in klinische stadia.

Over het bedrijf

ENLV fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 22.7% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft geen betekenisvolle marktkapitalisatie ( $28M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Enlivex Therapeutics Ltd. Concurrenten

Longeveron

NasdaqCM:LGVN

US$32.3m

Estrella Immunopharma

NasdaqCM:ESLA

US$30.8m

Burning Rock Biotech

NasdaqGM:BNR

US$30.9m

Acurx Pharmaceuticals

NasdaqCM:ACXP

US$30.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Enlivex Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$1.27
52 Week Hoogtepunt	US$4.59
52 Week Laag	US$1.15
Bèta	1.04
11 maand verandering	-16.99%
3 maanden verandering	0.71%
1 Jaar Verandering	-33.16%
33 jaar verandering	-84.92%
5 jaar verandering	-83.18%
Verandering sinds IPO	-87.67%

Recent nieuws en updates

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

Recent updates

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Apr 04

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Dec 13

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Jul 25

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Apr 05

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Nov 16

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30

Enlivex to gets US patent covering use of cell therapy Allocetra

Sep 06

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Aug 29

Envilex Therapeutics reports Q2 results

Aug 22

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Jul 08

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul 06

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Mar 23

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Nov 25

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Aug 12

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Jun 15

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Jan 11

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

Nov 19

Rendement voor aandeelhouders

	ENLV	US Biotechs	US Markt
7D	-8.0%	1.6%	2.3%
1Y	-33.2%	23.6%	35.1%

Rendement versus industrie: ENLV presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 23.6 % opleverde.

Rendement versus markt: ENLV presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 35.1 % opleverde.

Prijsvolatiliteit

Is ENLV's price volatile compared to industry and market?
ENLV volatility
ENLV Average Weekly Movement	9.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ENLV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ENLV is het afgelopen jaar gedaald van 15% naar 10%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	n/a	Oren Hershkovitz	www.enlivex.com

Enlivex Therapeutics Ltd. is, samen met haar dochterondernemingen, actief als een bedrijf in Israël dat zich bezighoudt met macrofaagherprogrammering van immuuntherapieën in klinische stadia. Zijn productpijplijn is Allocetra, dat zich in fase II van de klinische studie bevindt voor de behandeling van orgaan disfunctie veroorzaakt door sepsis. Het bedrijf ontwikkelt ook Allocetra voor de behandeling van matige knieartrose en knieartrose in het eindstadium, dat zich in fase I/II van de klinische studie bevindt.

Enlivex Therapeutics Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Enlivex Therapeutics zich tot de beurswaarde?
ENLV fundamentele statistieken
Marktkapitalisatie	US$27.51m
Inkomsten(TTM)	-US$22.29m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.2x

Koers/Winstverhouding

Is ENLV overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ENLV resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$22.29m
Inkomsten	-US$22.29m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.04
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ENLV op de lange termijn?

Bekijk historische prestaties en vergelijking

ENLV Overzicht aandelen

Beloningen

Risicoanalyse

Enlivex Therapeutics Ltd. Concurrenten

NasdaqCM:LGVN

US$32.3m

NasdaqCM:ESLA

US$30.8m

NasdaqGM:BNR

US$30.9m

NasdaqCM:ACXP

US$30.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Recent updates

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased by 20% to US$12.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Intends to Reduce its Workforce by Approximately 50%

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

New major risk - Financial position

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$15.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Envilex Therapeutics reports Q2 results

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Price target increased to US$33.00

Insufficient new directors

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece